Boston Scientific's drug-coated device, Agent, received FDA approval to treat coronary in-stent restenosis (ISR), a common complication of heart stent implantation. The device, the first of its kind in the US, utilizes a balloon catheter coated with paclitaxel to prevent ISR recurrence by transferring the drug to the vessel wall. Boston Scientific expects rapid adoption due to its efficacy in treating ISR, as demonstrated by statistically significant superiority in clinical trials. The approval follows positive results from a study involving 480 patients, where the device significantly reduced complications compared to uncoated alternatives.
Like
Save
Share